{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-007035","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.181807+00:00","generated_at":"2026-06-05T11:25:13.716092+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Esperion Q4/FY23 revenue growth 72%/54%; litigation resolved with $100M payment; FDA PDUFA March 31","bullets":["FY23 U.S. net product revenue $78.3M (+40% YoY); total revenue $116.3M (+54% YoY).","Q4 U.S. net product revenue $20.8M (+39% YoY); total revenue $32.3M (+72% YoY).","Litigation with DSE resolved; $100M received Jan 2024, additional $25M pending EMA label determination.","FDA PDUFA date March 31, 2024 for CV risk reduction label; Otsuka JNDA filing on track for 2024.","Cash position boosted by $90.8M net equity offering and $100M litigation payment; 2024 OpEx guidance $225-245M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-007035","json":"https://secwatch.observer/filing/0001628280-24-007035.json","markdown":"https://secwatch.observer/filing/0001628280-24-007035.md","text":"https://secwatch.observer/filing/0001628280-24-007035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828024007035/0001628280-24-007035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828024007035/espr-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T11:25:13.716092+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ed559338f39e277a1352639cb7ee3cd7107194fa","claim":"Esperion Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $32.3 million for the three months ended December 31, 2023, and $116.3 million for the full year ended December 31, 2023.","evidence_excerpt":"Esperion (NASDAQ: ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828024007035/0001628280-24-007035-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$32.3 million for the three months ended December 31, 2023, and $116.3 million for the full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}